• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . High Titers of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity

tetano

Editor, Senior Moderator
Front Immunol


. 2022 Apr 13;13:867716.
doi: 10.3389/fimmu.2022.867716. eCollection 2022.
High Titers of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity


Jan Hendriks[SUP] 1 [/SUP], Richard Schasfoort[SUP] 2 [/SUP], Michelle Koerselman[SUP] 1 [/SUP], Maureen Dannenberg[SUP] 2 [/SUP], Alexander Daniel Cornet[SUP] 3 [/SUP], Albertus Beishuizen[SUP] 3 [/SUP], Job van der Palen[SUP] 4 5 [/SUP], Johannes Krabbe[SUP] 6 7 [/SUP], Alide H L Mulder[SUP] 6 8 [/SUP], Marcel Karperien[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Almost 2 years from the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there is still a lot unknown how the humoral response affects disease progression. In this study, we investigated humoral antibody responses against specific SARS-CoV2 proteins, their strength of binding, and their relationship with COVID severity and clinical information. Furthermore, we studied the interactions of the specific receptor-binding domain (RBD) in more depth by characterizing specific antibody response to a peptide library.
Materials and methods: We measured specific antibodies of isotypes IgM, IgG, and IgA, as well as their binding strength against the SARS-CoV2 antigens RBD, NCP, S1, and S1S2 in sera of 76 COVID-19 patients using surface plasmon resonance imaging. In addition, these samples were analyzed using a peptide epitope mapping assay, which consists of a library of peptides originating from the RBD.
Results: A positive association was observed between disease severity and IgG antibody titers against all SARS-CoV2 proteins and additionally for IgM and IgA antibodies directed against RBD. Interestingly, in contrast to the titer of antibodies, the binding strength went down with increasing disease severity. Within the critically ill patient group, a positive association with pulmonary embolism, d-dimer, and antibody titers was observed.
Conclusion: In critically ill patients, antibody production is high, but affinity is low, and maturation is impaired. This may play a role in disease exacerbation and could be valuable as a prognostic marker for predicting severity.

Keywords: COVID-19; SPRi (surface plasmon resonance imagery); antibodies; immunoassay; infectious diseases; viral infection.
 
Back
Top Bottom